Tovorafenib for children and young adults with craniopharyngioma
Treatments studied
Part of Cancer clinical trials.
This trial studies tovorafenib to treat craniopharyngioma in children and young adults. It aims to shrink the tumor or slow its growth, and to learn which patients benefit most and what side effects to expect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 1 to 39.
- You have craniopharyngioma confirmed (newly diagnosed by brain-scan review, or recurrent by prior diagnosis or confirmed tissue).
- You must be able to have surgery for biopsy or tumor removal; if surgery isn’t possible, the team may enroll you only if you can provide older tumor tissue slides/blocks.
- You must have adequate “body readiness” lab results (bone marrow, kidney, liver) and generally be stable enough to participate (activity level limits apply).
- If you are having (or recently had) treatments like chemotherapy or radiation, enough time must have passed since the last dose and you must be recovered from side effects.
- If you take dexamethasone (a steroid), your dose must be stable or decreasing for at least 1 week before starting the trial, and your steroid dose must be limited.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a targeted treatment for adults with papillary craniopharyngioma that has a specific BRAF change (V600E). It may help shrink or control the tumor, especially when surgery is not expected to remove it safely.
This Phase 2 trial tests tovorafenib (DAY101) to treat children and young people whose Langerhans cell histiocytosis (LCH) is getting worse, came back, or did not respond to prior treatment. It may help by targeting certain gene changes found in the LCH.
This trial tests two targeted drugs (dabrafenib and trametinib) for children and young adults with a specific type of low-grade brain tumor that has a BRAF V600 mutation. The drugs work by blocking signals that help the tumor grow.
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
This trial tests a drug called tovorafenib for children and young adults with certain types of brain tumors that have specific genetic changes. It is aimed at helping people who have just finished radiation therapy.
This trial is testing a combination of two drugs, vinblastine and tovorafenib, for children and young adults (up to age 25) whose low-grade glioma has come back or worsened after prior treatment. It is for people whose tumor has a specific change in a gene called BRAF or CRAF.
Hear when a new Craniopharyngioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.